Introduction
Hypertension is a complex multifactorial disorder whose pathogenesis is approximately 30% genetically determined (1) . The reverse genetic approach has revealed the imporof left ventricular hypertrophy (LVH). The insertion/deletion polymorphism (I/D) of angiotensin converting enzyme gene (ACE) are strongly associated with plasma and cellular ACE levels, and has been suggested to be a risk factor for the development and/or progression of several cardiovascular diseases, including LVH (8) (9) (10) . On the other hand, the kallikrein-kinin system (KKS) also plays a critical role in the cardiovascular system, affecting blood pressure regulation, cell proliferation and matrix synthesis by fibroblasts (11, 12) . Histological and morphological analyses have revealed ventricular hypertrophy and cardiomyocyte enlargement in the bradykinin B2 receptor gene (BDKRB2) knockout mice (13) . Recently, the human BDKRB2 was implicated as a candidate in the complex genetic underpinning of essential hypertension and cardiovascular disease. Subsequent studies of the genomic structure have shown that it is characterized by 3 polymorphisms respectively located in each of the 3 exons and 1 polymorphism located in the promoter region (14) (15) (16) . The polymorphism ( 58T/C) in the promoter region of the BDKRB2 was associated with the occurrence of essential hypertension, and the cardioprotective effect of ACE-inhibitor (12, (17) (18) (19) . The 9/ 9 polymorphism ( 9/ 9: 9 bp insertion/deletion) in exon 1 of the BDKRB2 was shown to be strongly associated with left ventricular (LV) growth response in normotensive men undergoing physical training, and the change in LV mass in response to antihypertensive treatment (20) . These results suggest that the human BDKRB2 is one of the candidate genes involved in hypertension and LVH.
We have carried out a Japanese case-control study to examine the genetic involvement of BDKRB2 and ACE in the pathogenesis of hypertension and LVH.
Methods

Population
Patients with essential hypertension and control subjects were recruited from among outpatients of Osaka University Hospital. All patients and control subjects were Japanese and gave their informed consent for genetic analysis before participating in the research protocol, which was approved by the Osaka University Ethics Committee. All patients (n 275) had a family history of hypertension in first-degree relatives and were diagnosed as having primary hypertension. Patients with secondary hypertension, diabetes mellitus, or apparent ischemic heart disease were excluded. The criteria for hypertension were defined as systolic blood pressure (SBP) higher than 160 mmHg, diastolic blood pressure (DBP) higher than 95 mmHg, or chronic antihypertensive therapy. LVH was detected by ECG using Sokolow and Lyon criteria at rest in 242 untreated patients with hypertension. Control subjects (n 441), who had no history of hypertension or diabetes mellitus, were recruited from the same population and were sex-matched to the hypertensive subjects. Normotension was defined as SBP <130 mmHg, DBP <90 mmHg, and lack of current antihypertensive drug treatment. We also excluded from the control group those subjects whose first-degree relatives had hypertension. Participants completed a standard questionnaire on their personal medical history and family history of hypertension. Blood pressure was measured twice, with the subject seated after 5 min of rest.
Determination of Genotypes
DNA was extracted from 200 µl buffy coat using a QIAamp Kit (QIAGEN, Valencia, USA), and genotypes of participants were determined using the TaqMan-polymerase chain reaction (PCR) method (21) . In the present study, we prepared two probes: a C allele-specific probe, 5 -Fam-TGAC ATCACTACCCAGC-Tamra-3 , and a T allele-specific probe, 5 -Vic-ATGACATCATTACCCAGC-Tamra-3 . Each of the reporters was quenched by Vic and was typically located at the 3 end. The design of primers for PCR of the flanking region of the polymorphism ( 58T/C) in the promoter of BDKRB2 was as follows: forward, 5 -GGAAGTG CCCAGGAGGCT-3 ; reverse, 5 -CGGCGGGAACAGCTC AT-3 . PCR was carried out using a GeneAmp PCR System 9700 thermal cycler (Applied Biosystems, Foster City, USA). The PCR protocol was as follows: initial denaturation at 95 ºC for 10 min, followed by 40 cycles of 95 ºC for 15 s and 60 ºC for 60 s. The fluorescence level of PCR products was measured using an ABI PRISM 7200 and 7900 Sequence Detector (Applied Biosystems), which resulted in three genotypes of the BDKRB2 being clearly identified. The exon 1 9/ 9 polymorphism of the BDKRB2 and the I/D polymorphism of ACE were determined by the PCR-restriction fragment length polymorphism (RFLP) method (15) .
Statistical Analysis
All statistical analyses were conducted using StatView 4.5J (Abacus Concepts, Berkeley, USA) and JMP 5.0.1 (SAS Inc., Cary, USA) software. The difference in genotype distribution between the patients and control subjects was examined by χ 2 analysis. The association between the polymorphism and each value of classical risk factors for hypertension was examined by one-way ANOVA. To assess the quantitative effects of covariates (sex, age, body mass index [BMI] and triglyceride [TG] concentration), multiple logistic regression analysis was performed using JMP 5.0.1 software. Table 1 summarizes the clinical data of hypertensives and normotensives, and Table 2 the clinical data in untreated hypertensives with and without LVH. The hypertensive group had significantly higher SBP, DBP, BMI, high density lipoprotein (HDL) cholesterol, TG and fasting plasma glu-cose (FPG), but the age was younger compared with the control group. However, no significant difference was observed in the values of other risk factors for hypertension, such as total cholesterol (T-chol), between hypertensives and normotensives. In the groups with and without LVH, the only significant difference was in BMI, which was lower in the former group.
Results
The genotypes of the polymorphism ( 58T/C and 9/ 9) of the BDKRB2 gene and I/D polymorphism of the ACE gene in all subjects were clearly determined by TaqMan-PCR or gel electrophoresis after PCR methods. The distribution of genotypes did not significantly deviate from Hardy-Weinberg's expectation in either the hypertensive or control group. The genotype distribution of BDKRB2 polymorphism ( 58T/C) was similar to that in a previous association study in Japanese by Mukae et al. (17) (18) . Even though the 9 allele was common (allele frequency >0.50) in Caucasians or AfricanAmericans, there was no 9 variant within the Japanese population (22) . The genotype and allele distributions were not significantly different between hypertensives and normotensives, suggesting that the polymorphism ( 58T/C and exon 1 9/ 9) of the BDKRB2 gene and I/D of ACE were not significantly associated with hypertension in this study (Table 3) . On the other hand, the genotype and allele of the polymorphism ( 58T/C) in the promoter region of the BDKRB2 genotype were associated with LVH in hypertensive subjects (genotype: p 0.048, χ Table 4 ). In contrast, ACE I/D was not, in itself, associated with LVH in hypertensives (Table 4) . However, the prevalence of LVH was higher than 50% in the subjects with both the BDKRB2 CC and D allele of ACE, suggesting that there was a synergistic effect between the BDKRB2 promoter polymorphism and ACE I/D polymorphism (Table 5 ). After adjustment for a possible confounding factor (BMI), hypertensives with both the BDKRB2 CC and ACE D allele were significantly more predisposed to LVH than those with other genotypes (Wald χ 2 6.5, p 0.01), and the calculated odds ratio for LVH was 3.77 (95% CI: 1.41-11.2), as shown in Fig. 1 .
Discussion
Many epidemiological studies have suggested that there is a strong genetic component to essential hypertension. More recently, experimental data have shown a protective role of the BDKRB2 in the development of hypertension and cardiovascular pathology (23) (24) (25) . The involvement of the KKS in cardiac hypertrophy and microvascular disease has been confirmed in recent studies using a BDKRB2 knockout mouse model, but basal SBP levels did not differ between BDKRB2 knockout and wild-type mice (13, 26) . In humans, the prevalence of salt-sensitive hypertension has been reported to be higher in Afro-Americans than in Caucasians (27) . In addition, only a few papers using a small number of cases and controls have been published concerning the role of the BDKRB2 promoter region in the genetic predisposition to essential hypertension (17, 18, 28) . We found that the prevalence of the 58T allele of BDKRB2 was significantly high- (29) . Brull et al. showed that the exon 1 9/ 9 polymorphism of BDKRB2 was strongly associated with LV growth response in normotensive white men undergoing a 10-week physical training program (30). Hallberg et al. concluded that the BDKRB2 genotype influences not only exercise-induced LV growth in normotensive people, but also LV mass regression during antihypertensive treatment with two common antihypertensive drugs (20) . In addition, Aoki et al. reported that a significantly higher prevalence of the 58C allele of the BDKRB2 was seen in acute myocardial infarction patients with hypertension compared with those without hypertension (22) . Even though we found a significant association between BDKRB2 polymorphism and LVH in hypertensives, we did not find that the polymorphism increased the risk for hypertension and ischemic heart disease.
Kammerer et al. reported that the promoter and exon 1 regions are related to transcription rate (15). Braun et al. also reported that polymorphism of the promoter region may influence the transcription rate of the gene. Furthermore, they performed luciferase reporter gene assays to examine the effect of the two different alleles of the promoter on the transcription rate in human kidney cells, and the luciferase promoter assay of 58T was found to show higher expression than that of 58C (14) . Our data suggest that the low transcriptional activity of the BDKRB2 promoter polymorphism may cause the development of LVH in hypertensives.
On the other hand, the D allele of ACE was not directly associated with an increased risk for LVH in hypertensives, but rather achieved this association synergistically in combination with the BDKRB2 promoter polymorphism (Table 5 , Fig. 1 ). ACE not only generates angiotensin II but also degrades bradykinin, and the type 1 receptor of angiotensin II and the BDKRB2 communicate directly with each other (31, 32) . The BDKRB2 antagonist significantly attenuated the antihypertensive effect of ACE inhibitors in humans, and the cardioprotective effect of ACE inhibitors was lost in BDKRB2 knock-out mice (26, 29, 33, 34) . Several studies have shown that the ACE genotype plays a role in LVH growth in response to exercise, with a greater increase in LV mass in patients with the DD and ID genotype (35) (36) (37) . ACE activity influences LVH: the deletion (D), rather than the insertion (I), polymorphic variant of the ACE gene is associated with higher left ventricular ACE activity (38) and a greater growth response (39) . This effect might be mediated through increased synthesis of the growth factor angiotensin II, or by degradation of growth-inhibitory kinins (40) . Taken together, our results suggest that two alterations, the lower expression of BDKRB2 due to T-to-C nucleotide substitution at position 58 and the activation of the cardiac renin-angiotensin system by the ACE D allele, synergistically enhanced the development of LVH in untreated hypertensive subjects.
However, there were several limitations in the present study. LVH was only estimated by ECG, so that there may have been a discrepancy from the actual LVH quantified by echocardiography. The number of subjects in this study was not sufficient and, therefore, its results cannot be directly extrapolated to associations of these polymorphisms with LVH in hypertensive subjects. Because of the small size of the study population, these results should be considered preliminary until replicated in another study. More in vitro studies are warranted to demonstrate the effect of these polymorphisms on cardiovascular function and morbidity.
In conclusion, our study indicates that the polymorphism ( 58T/C) in the promoter region of the BDKRB2 is a risk factor and has a synergetic effect with the ACE I/D polymorphism for LVH in untreated hypertensive subjects, but is not associated with hypertension in the Japanese population. 
